These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 21838863)
1. Latent HIV in primary T lymphocytes is unresponsive to histone deacetylase inhibitors. Sahu GK; Cloyd MW Virol J; 2011 Aug; 8():400. PubMed ID: 21838863 [TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921 [TBL] [Abstract][Full Text] [Related]
3. Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. Shan L; Xing S; Yang HC; Zhang H; Margolick JB; Siliciano RF J Antimicrob Chemother; 2014 Jan; 69(1):28-33. PubMed ID: 23999005 [TBL] [Abstract][Full Text] [Related]
4. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors. Painter MM; Zaikos TD; Collins KL J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396 [TBL] [Abstract][Full Text] [Related]
5. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb. Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990 [TBL] [Abstract][Full Text] [Related]
6. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. Banga R; Procopio FA; Cavassini M; Perreau M J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693 [TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454 [TBL] [Abstract][Full Text] [Related]
8. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407 [TBL] [Abstract][Full Text] [Related]
9. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Rasmussen TA; Schmeltz Søgaard O; Brinkmann C; Wightman F; Lewin SR; Melchjorsen J; Dinarello C; Østergaard L; Tolstrup M Hum Vaccin Immunother; 2013 May; 9(5):993-1001. PubMed ID: 23370291 [TBL] [Abstract][Full Text] [Related]
10. Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir. Ling L; Kim M; Soper A; Kovarova M; Spagnuolo RA; Begum N; Kirchherr J; Archin N; Battaglia D; Cleveland D; Wahl A; Margolis DM; Browne EP; Garcia JV mBio; 2024 Sep; 15(9):e0163224. PubMed ID: 39136440 [TBL] [Abstract][Full Text] [Related]
11. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922 [TBL] [Abstract][Full Text] [Related]
18. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'. Cohen J Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956 [No Abstract] [Full Text] [Related]
19. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation. Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439 [TBL] [Abstract][Full Text] [Related]
20. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]